TNF and rheumatoid arthritis: The expanding compendium of targeted therapies for RA includes inhibitors of TNF-α (infliximab, adalimumab, etanercept and the newer antibodies golimumab and certolizumab pegol), rituximab which targets the B-cell specific CD 20 antigen, the T cell costimulation inhibitor abatacept and the IL-6 receptor inhibitor tocilizumab.